Supreme Court Could Curtail Mifepristone Access, Lay Out ‘Road Map’ To Challenge FDA Approvals

 
• By Brenda Sandburg

Court decision on whether an anti-abortion group has standing to challenge FDA actions could dispose of case or open door to similar suits. Ruling will determine if pre-2016 REMS restrictions are reinstated.

Supreme Court long shot
US Supreme Court to decide whether FDA should not have eased restrictions on access to mifepristone • Source: Brenda Sandburg

More from US FDA

More from Agency Leadership